TY - JOUR
T1 - Home Monitoring to Detect Progression of Interstitial Lung Disease
T2 - A Prospective Cohort Study
AU - Althobiani, Malik A
AU - Ranjan, Yatharth
AU - Russell, Anne-Marie
AU - Jacob, Joseph
AU - Orini, Michele
AU - Sankesara, Heet
AU - Conde, Pauline
AU - Rashid, Zulqarnain
AU - Dobson, Richard
AU - Hurst, John
AU - Porter, Joanna
AU - Folarin, Amos
PY - 2024/4/8
Y1 - 2024/4/8
N2 - In this prospective observational cohort study, 20 IPF and non-IPF patients, as diagnosed by a multidisciplinary team were recruited from the University College London Hospital (UCLH) between August 2021 and January 2022 using 2018 ATS criteria. Patients who met the criteria for ILD other than IPF, including those with sarcoidosis, and hypersensitivity pneumonitis, were grouped together as non-IPF. They were monitored over 26 weeks using the RADAR-Base mHealth platform. Data collection tools included: questionnaires, a Garmin wearable device, finger pulse oximeter and a NuvoAir smart-spirometer.7 In addition, participants underwent lung function testing in a hospital setting as part of their usual hospital visits. Patients were divided into two groups: progressed and stable. Progression was defined as a ≥5% decline in forced vital capacity (FVC) at6 months by hospital-based spirometry and/or death.
AB - In this prospective observational cohort study, 20 IPF and non-IPF patients, as diagnosed by a multidisciplinary team were recruited from the University College London Hospital (UCLH) between August 2021 and January 2022 using 2018 ATS criteria. Patients who met the criteria for ILD other than IPF, including those with sarcoidosis, and hypersensitivity pneumonitis, were grouped together as non-IPF. They were monitored over 26 weeks using the RADAR-Base mHealth platform. Data collection tools included: questionnaires, a Garmin wearable device, finger pulse oximeter and a NuvoAir smart-spirometer.7 In addition, participants underwent lung function testing in a hospital setting as part of their usual hospital visits. Patients were divided into two groups: progressed and stable. Progression was defined as a ≥5% decline in forced vital capacity (FVC) at6 months by hospital-based spirometry and/or death.
UR - https://onlinelibrary.wiley.com/journal/14401843
U2 - https://doi.org/10.1111/resp.14708
DO - https://doi.org/10.1111/resp.14708
M3 - Letter
SN - 1323-7799
SP - 1
EP - 5
JO - Respirology
JF - Respirology
M1 - RES-24-1010.R1
ER -